<DOC>
	<DOCNO>NCT00425516</DOCNO>
	<brief_summary>Neoadjuvant chemotherapy , know `` first '' `` induction chemotherapy '' therapeutic assumption breast cancer base narrow dependence preclinically reveal primary tumour , tumoral angiogenesis growth distant metastasis . The result Aberdeen Group ( Smith et al , 2002 ; Hutcheon et al , 2003 ) , NSABP B27 trial ( Bear et al , 2003 ) Gepar-Duo Group ( Von Minckwitz et al , 2002 ) show sequential protocol , use docetaxel anthracycline-based combination , allow well clinical response lead frequent conservative surgery , importantly , increase rate complete pathological response , assess good efficacy . The use reference adjuvant protocol neo-adjuvant treatment fully admissible 7 randomized trial show perfect equivalence adjuvant protocol chemotherapy give induction treatment Even keep principle sequential treatment , crucial question know sequential treatment patient , oncologist could get good complete pathological response , disease-free overall survival rate adaptation treatment objective result begin 2 FEC 100 course modulation follow course . We use primary regimen 3 FEC cycle + 3 TAXOTERE cycle , standard adjuvant regimen ( noted Temporary Protocol Treatment Inca page 5 ( October 2005 ) well Saint Paul de Vence 2005 recommendation adjuvant chemotherapy ( Oncologie -- volume 7 - N°5 , August 2005 , p 370 ) . This standard treatment compare chemotherapy modulate repartition accord result obtain subsequent tumor evaluation induction therapy .</brief_summary>
	<brief_title>Breast Cancer Treated Neoadjuvant Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Patient histological proof non metastatic breast cancer , whose clinical tumor diameter &gt; 2 cm , &lt; 2 cm , situate areolar area nipple . T2T3 , N0N1 tumor , noninflammatory , unilateral , nonmetastatic , grade II III , HER2neu negative , without extension beyond breast axillar area . Performance Status = 01 WHO . Patient non pretreated breast cancer . Patient without cardiac pathology without anthracyclines contraindication ( assess normal ejection fraction ) . Normal haematological , renal hepatic function : PNN &gt; 2.109 /l , platelet &gt; 100 . 109 /l , Hb &gt; 10 g/dl , normal bilirubin serum , ASAT ALAT &lt; 2,5 ULN , alkaline phosphatase &lt; 2,5 ULN , creatinin &lt; 140 µmol/l creatinin clearance &gt; 60 ml/min Written inform consent date sign patient All breast cancer describe inclusion criterion , particular inflammatory and/or neglect ( T4b T4d ) form . Patient present plurifocal tumor , multicentric tumor , bilateral tumor . Grade I well differentiate tumor . HER2 neu 3 + ( ICH FISH CISH ) tumor . Non measurable lesion , two diameter , whatever radiological method use . Patient present microcalcifications breast conservation possible . Patient already operate breast cancer primary axillar node dissection . Patient antecedent cancer , exception situ uterine cervix basocellular skin cancer , consider heal . Patient present another pathology consider incompatible patient inclusion study Patient receive treatment investigational drug participate another clinical study delay &lt; 30 day pretreated cytostatic chemotherapy . Antecedents allergy polysorbate 80 . Patient pregnant lactate use effective contraceptive method . Any psychological , familial , sociological geographical condition may potentially hamper compliance study protocol follow schedule , assess patient prior registration trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>breast cancer</keyword>
	<keyword>sequential treatment</keyword>
</DOC>